Vita 34 AG: Management and supervisory board rely on continuity in the corporation

Vita 34 AG  / Key word(s): Change of Personnel

01.08.2014 18:27

Dissemination of an Ad hoc announcement according to § 15 WpHG, transmitted
by DGAP - a service of EQS Group AG.
The issuer is solely responsible for the content of this announcement.


Vita 34 AG: Management and supervisory board rely on continuity in the

  - Management contract extended: Dr. André Gerth reappointed as CEO until

  - Internal changeover in supervisory board: Dr. Giering takes seat of
    chairman of supervisory board; previous chairman Dr. Födisch remains
    member of the board

Leipzig, 1 August 2014 -Vita 34 AG (WKN A0BL84), the largest private stem
cell bank in the German-speaking countries, provides for continuity in the
corporation by reappointing Dr. André Gerth as CEO until 2018 and an
internal changeover in the supervisory board.

In today's meeting the supervisory board of Vita 34 AG has reappointed Dr.
Gerth as the corporation's CEO from 1 August 2014 to 31 December 2018. The
supervisory board thus expresses once again its confidence in Dr. Gerth and
recognizes his previous performance as CEO of Vita 34 AG. Beyond that, Dr.
Gerth emphasizes his commitment to Vita 34 AG by extending the lock-up
agreement for his Vita 34 shares by another 18 months. The management board
appreciates Dr. Gerth's clear proof of confidence.

At the same time, the supervisory board elected Dr. Hans-Georg Giering, so
far vice chairman of the supervisory board, the new chairman. He takes over
the position from Dr. Holger Födisch with immediate effect. Dr. Giering has
approved expertise from acting as the CEO of a quoted, successful company
for almost 15 years. He will contribute this experience to his new position
as the chairman of the supervisory board at Vita 34 AG. Dr. Födisch will
continue to actively support the corporation as vice chairman of the
supervisory board in the future.

01.08.2014 The DGAP Distribution Services include Regulatory Announcements,
Financial/Corporate News and Press Releases.
Media archive at and

Language:     English
Company:      Vita 34 AG
              Deutscher Platz 5a
              04103 Leipzig
Phone:        +49(0341)48792-40
Fax:          +49(0341)48792-39
ISIN:         DE000A0BL849
WKN:          A0BL84
Listed:       Regulierter Markt in Frankfurt (Prime Standard); Freiverkehr
              in Berlin, Düsseldorf, Hamburg, München, Stuttgart
End of Announcement                             DGAP News-Service